dihydroxyphenylalanine has been researched along with Abnormal Movements in 10 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-four patients with advanced Parkinson's disease participated in a prospective 24-month double-blind, placebo-controlled trial of fetal nigral transplantation." | 2.71 | A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. ( Brin, MF; Freeman, TB; Godbold, J; Goetz, CG; Kordower, JH; Nauert, GM; Olanow, CW; Perl, DP; Shannon, KM; Sossi, V; Stoessl, AJ, 2003) |
| "Persistent dyskinesias in the absence of or with only minimal amounts of dopaminergic medication have been reported after dopamine cell implantation for Parkinson's disease." | 2.70 | Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. ( Breeze, R; Dhawan, V; Eidelberg, D; Fahn, S; Feigin, A; Freed, C; Fukuda, M; Greene, P; Ma, Y; Shi, Q, 2002) |
| "Graft-induced dyskinesias are serious adverse effects and a major roadblock for the further development of cell therapies, and functional imaging can help investigate the mechanisms underlying their cause." | 2.46 | Brain imaging after neural transplantation. ( Piccini, P; Politis, M, 2010) |
| "The onset of wearing-off and dyskinesias was determined based on blinded clinical assessments and patient records." | 1.43 | Putaminal dopamine turnover in de novo Parkinson disease predicts later motor complications. ( Beuthien-Baumann, B; Kotzerke, J; Löhle, M; Mende, J; Oehme, L; Reichmann, H; Storch, A; van den Hoff, J; Wolz, M, 2016) |
| "Graft-induced dyskinesias are a serious complication after neural transplantation in Parkinson's disease." | 1.37 | Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. ( Bjorklund, A; Brooks, DJ; Lindvall, O; Oertel, WH; Piccini, P; Pogarell, O; Politis, M; Quinn, NP; Wu, K, 2011) |
| "Parkinsonism was induced using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine." | 1.32 | Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. ( Bezard, E; Di Monte, DA; Hsu, A; Langston, JW; Quik, M; Sokoloff, P; Togasaki, DM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Löhle, M | 1 |
| Mende, J | 1 |
| Wolz, M | 1 |
| Beuthien-Baumann, B | 1 |
| Oehme, L | 1 |
| van den Hoff, J | 1 |
| Kotzerke, J | 1 |
| Reichmann, H | 1 |
| Storch, A | 1 |
| Lipton, J | 1 |
| Rivkin, MJ | 1 |
| Politis, M | 2 |
| Piccini, P | 3 |
| Oertel, WH | 1 |
| Wu, K | 1 |
| Quinn, NP | 1 |
| Pogarell, O | 1 |
| Brooks, DJ | 1 |
| Bjorklund, A | 1 |
| Lindvall, O | 1 |
| Ma, Y | 1 |
| Feigin, A | 1 |
| Dhawan, V | 1 |
| Fukuda, M | 1 |
| Shi, Q | 1 |
| Greene, P | 1 |
| Breeze, R | 1 |
| Fahn, S | 1 |
| Freed, C | 1 |
| Eidelberg, D | 1 |
| Ceballos-Baumann, AO | 1 |
| Olanow, CW | 1 |
| Goetz, CG | 1 |
| Kordower, JH | 1 |
| Stoessl, AJ | 1 |
| Sossi, V | 1 |
| Brin, MF | 1 |
| Shannon, KM | 1 |
| Nauert, GM | 1 |
| Perl, DP | 1 |
| Godbold, J | 1 |
| Freeman, TB | 1 |
| Hsu, A | 1 |
| Togasaki, DM | 1 |
| Bezard, E | 2 |
| Sokoloff, P | 1 |
| Langston, JW | 1 |
| Di Monte, DA | 1 |
| Quik, M | 1 |
| Gold, SJ | 1 |
| Hoang, CV | 1 |
| Potts, BW | 1 |
| Porras, G | 1 |
| Pioli, E | 1 |
| Kim, KW | 1 |
| Nadjar, A | 1 |
| Qin, C | 1 |
| LaHoste, GJ | 1 |
| Li, Q | 1 |
| Bioulac, BH | 1 |
| Waugh, JL | 1 |
| Gurevich, E | 1 |
| Neve, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Embryonic Dopamine Cell Implants for Parkinson's Disease: A Double-Blind Study[NCT00038116] | Phase 3 | 40 participants (Actual) | Interventional | 1995-05-31 | Completed | ||
| STEM-PD Trial: A Multicentre, Single Arm, First in Human, Dose-escalation Trial, Investigating the Safety and Tolerability of Intraputamenal Transplantation of Human Embryonic Stem Cell Derived Dopaminergic Cells for Parkinson's Disease (STEM-PD Product)[NCT05635409] | Phase 1 | 8 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for dihydroxyphenylalanine and Abnormal Movements
| Article | Year |
|---|---|
Brain imaging after neural transplantation.
Topics: Animals; Brain; Brain Tissue Transplantation; Cerebral Cortex; Clinical Trials as Topic; Corpus Stri | 2010 |
Functional imaging in Parkinson's disease: activation studies with PET, fMRI and SPECT.
Topics: Brain; Brain Mapping; Diagnosis, Differential; Dihydroxyphenylalanine; Dyskinesias; Electric Stimula | 2003 |
Dyskinesias after transplantation in Parkinson's disease.
Topics: Animals; Brain Tissue Transplantation; Dihydroxyphenylalanine; Dyskinesias; Fetal Tissue Transplanta | 2002 |
2 trials available for dihydroxyphenylalanine and Abnormal Movements
| Article | Year |
|---|---|
Dyskinesia after fetal cell transplantation for parkinsonism: a PET study.
Topics: Adult; Brain; Caudate Nucleus; Cohort Studies; Dihydroxyphenylalanine; Double-Blind Method; Dyskines | 2002 |
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.
Topics: Adult; Aged; Brain Tissue Transplantation; Cell Survival; Dihydroxyphenylalanine; Dopamine; Double-B | 2003 |
5 other studies available for dihydroxyphenylalanine and Abnormal Movements
| Article | Year |
|---|---|
Putaminal dopamine turnover in de novo Parkinson disease predicts later motor complications.
Topics: Aged; Dihydroxyphenylalanine; Dopamine; Dopamine Agents; Dyskinesias; Female; Fluorodeoxyglucose F18 | 2016 |
16p11.2-related paroxysmal kinesigenic dyskinesia and dopa-responsive parkinsonism in a child.
Topics: Adolescent; Chromosomes, Human, Pair 16; Dihydroxyphenylalanine; Dyskinesias; Humans; Male; Middle A | 2009 |
Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio.
Topics: Brain Mapping; Brain Tissue Transplantation; Corpus Striatum; Dihydroxyphenylalanine; Dopamine Plasm | 2011 |
Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys.
Topics: Animals; Dihydroxyphenylalanine; Disease Models, Animal; Drug Interactions; Dyskinesias; Female; Par | 2004 |
RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Corpus Striatum; Dihydroxyphenylalanine; Disease Mo | 2007 |